Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14000465 | 0.87 | ATM (0.51) | ATML3MBTL1ALDH1A1CYP1A2CHRM3 | |
| SCHEMBL954586 | 0.87 | ATM (0.51) | ATML3MBTL1ALDH1A1CYP1A2CHRM3 | |
| SCHEMBL954588 | 0.87 | ATM (0.51) | ATML3MBTL1ALDH1A1CYP1A2CHRM3 | |
| SCHEMBL11725897 | 0.84 | ATM (0.49) | ATML3MBTL1ALDH1A1CYP1A2CHRM3 | |
| SCHEMBL11727212 | 0.83 | CHRM3 (0.52) | ATML3MBTL1ALDH1A1CYP1A2CHRM3 | |
| SCHEMBL13785557 | 0.82 | DRD2 (0.47) | CHRM3CHRM4CHRM5CHRM1CYP3A4 | |
| SCHEMBL14518960 | 0.81 | KCNH2 (0.44) | ALDH1A1CHRM3CHRM4CHRM5CHRM1 | |
| SCHEMBL13601296 | 0.81 | OPRM1 (0.44) | CHRM3CHRM4CHRM5CHRM1CYP3A4 | |
| SCHEMBL13785561 | 0.80 | CYP2J2 (0.49) | CHRM3CHRM4CHRM5CHRM1CYP3A4 | |
| SCHEMBL13785556 | 0.80 | CYP2J2 (0.51) | CHRM3CHRM4CHRM5CHRM1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615566-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080146649-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146649-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | ATM 3782/4885L3MBTL1 4423/4885ALDH1A1 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.